[Platelet aggregation inhibitors in the comprehensive treatment of bronchial asthma].
Platelet aggregation in infectious bronchial asthma patients was examined in vitro and in vivo upon administration of disaggregation agents trental, curantyl, sermion. A significant disaggregation related to trental and sermion action was recorded in vitro and in vivo as shown by hemolysate-aggregation test, ADP-induces aggregation, plasma levels of the platelet factor IV. Introduction of disaggregation agents in to combined therapy of infectious bronchial asthma contributes to more rapid arrest of bronchoconstriction in relevant patients.